U.S. markets open in 4 hours 40 minutes
  • S&P Futures

    4,298.25
    0.00 (0.00%)
     
  • Dow Futures

    33,895.00
    +22.00 (+0.06%)
     
  • Nasdaq Futures

    13,684.00
    +2.75 (+0.02%)
     
  • Russell 2000 Futures

    2,025.80
    +2.00 (+0.10%)
     
  • Crude Oil

    88.34
    -1.07 (-1.20%)
     
  • Gold

    1,791.30
    -6.80 (-0.38%)
     
  • Silver

    20.10
    -0.17 (-0.85%)
     
  • EUR/USD

    1.0143
    -0.0022 (-0.21%)
     
  • 10-Yr Bond

    2.7910
    0.0000 (0.00%)
     
  • Vix

    19.99
    +0.46 (+2.36%)
     
  • GBP/USD

    1.2039
    -0.0019 (-0.16%)
     
  • USD/JPY

    133.8250
    +0.5530 (+0.41%)
     
  • BTC-USD

    24,007.00
    -44.48 (-0.18%)
     
  • CMC Crypto 200

    569.80
    -20.96 (-3.55%)
     
  • FTSE 100

    7,537.71
    +28.56 (+0.38%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

NeuroSense Shares Surge On Encouraging Data From Alzheimer's-Associated Biomarker Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • NeuroSense Therapeutics Ltd (NASDAQ: NRSN) has announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD).

  • Earlier this week, NeuroSense reported results from a stage III ALS Biomarker study evaluating PrimeC.

  • Preliminary results showed that levels of disease-related biomarkers in people with ALS were unchanged, in contrast to a statistically significant decline in biomarkers when PrimeC was administered.

  • NeuroSense's biomarker study indicates that CogniC's mechanism of action may effectively target the pathways involved in the disease, such as miRNA dysregulation, lysosomal dysfunction, and impaired autophagy.

  • Additionally, hallmarks of AD were detected, such as increased levels of amyloid-β (Aβ) and intracellular aggregates of tau protein among the panel of biomarkers evaluated.

  • Preliminary results revealed high levels of TDP-43 in people who suffer from AD compared to the healthy control group.

  • NeuroSense says that CogniC has already been shown to impact TDP-43 in a Phase 2a clinical trial biomarker study in amyotrophic lateral sclerosis (ALS).

  • NeuroSense is conducting its AD biomarker study using Neuron-Derived Exosomes to observe key alterations in biomarkers.

  • Price Action: NRSN shares are up 62.4% at $4.45 during the premarket session on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.